ALLAIR 4mg Chewable tablet

What is ALLAIR 4mg

ALLAIR is a chewable tablet containing **4 mg montelukast sodium**, a leukotriene receptor antagonist prescribed primarily for pediatric patients (2–5 years) with asthma or allergic rhinitis. It is chewable, flavored for ease of administration, and supplied in blisters of 10 tablets (total 30 per pack).

• Drug class: Leukotriene receptor antagonist (LTRA).
• Indications: Approved to prevent and manage chronic asthma, relieve symptoms of perennial and seasonal allergic rhinitis, and prevent exercise-induced bronchoconstriction in this age group :contentReference[oaicite:1]{index=1}.
• Age group: Approved dose for 2–5 years as chewable; older children/adolescents use higher doses. Alternative forms (granules/tablets) available for other age groups :contentReference[oaicite:2]{index=2}.
• Administration route: Oral chewable tablet, typically taken once daily.

Summary: AN antihistamine alternative, ALLAIR helps control chronic airway inflammation and allergy symptoms in young children through a convenient and palatable chewable formulation.

How to use ALLAIR 4mg

• Dosing: One 4 mg chewable tablet once daily, taken in the evening for asthma or at a consistent time each day for allergy control :contentReference[oaicite:3]{index=3}.
• Administration: Chew thoroughly before swallowing. Can be taken with or without food.
• Missed dose: If a dose is missed, skip it and take the next dose at the usual time—do not double up :contentReference[oaicite:4]{index=4}.
• Duration: Use daily for maintenance. In children with asthma, ensure a rescue inhaler is available for acute episodes :contentReference[oaicite:5]{index=5}.
• Monitoring: Regular follow-ups are recommended to assess symptom control and watch for side effects.
• Storage before use: Keep tablets in blister packs until use to preserve taste and freshness.

Note: ALLAIR is not for acute asthma attacks—use a prescribed inhaler. Adjustments might be needed for renal/hepatic impairment under supervision.

Mode of Action ALLAIR 4mg

• Leukotriene receptor blockade: Montelukast selectively blocks cysteinyl leukotriene receptors (CysLT1), mitigating bronchoconstriction, inflammation, mucus secretion, and vascular permeability in the airways :contentReference[oaicite:6]{index=6}.
• Inhibition of leukotrienes: Prevents effects of LTC₄, LTD₄, and LTE₄—potent mediators in asthma and allergic rhinitis pathophysiology.
• Clinical effects: Reduces airway hyperresponsiveness and improves breathing in persistent asthma; alleviates nasal congestion, rhinorrhea, sneezing, and itching in allergic rhinitis :contentReference[oaicite:7]{index=7}.
• Prevention of exercise-induced bronchoconstriction: A single dose taken ≥2 hours before exercise provides protection lasting ~24 hours :contentReference[oaicite:8]{index=8}.

Key takeaway: ALLAIR offers targeted anti-inflammatory and bronchodilatory effects by blocking leukotriene-mediated pathways—providing effective symptom control for children.

ALLAIR 4mg Interactions ALLAIR 4mg

• Minimal drug–drug interactions: Montelukast is metabolized mainly via CYP2C8, CYP3A4, CYP2C9. Study data show no significant interactions with theophylline, prednisone/prednisolone, digoxin, warfarin, or oral contraceptives at clinical doses :contentReference[oaicite:9]{index=9}.
• CYP2C8 substrates: Theoretical increases in levels of drugs like amodiaquine due to enzyme inhibition—but clinically insignificant unless high-dose combinations are used :contentReference[oaicite:10]{index=10}.
• Phenobarbital/rifampin/gemfibrozil: May affect montelukast metabolism; monitor drug levels or clinical response :contentReference[oaicite:11]{index=11}.
• Aspirin-sensitive asthma: Continue avoidance—montelukast does not alter aspirin-induced bronchoconstriction risk :contentReference[oaicite:12]{index=12}.
• Vaccines: No noted interactions; immunizations can proceed as scheduled.
• Central nervous system depressants: No reported additive effects with benzodiazepines or antihistamines.

Recommendation: Always inform clinicians of all medications. While ALLAIR is relatively free of interactions, caution is advised with strong CYP-inducers/inhibitors and in aspirin-sensitive patients.

Dosage of ALLAIR 4mg

• Children 2–5 years: 4 mg chewable tablet once daily (approved indication) :contentReference[oaicite:13]{index=13}.
• Exercise-induced bronchoconstriction: Same 4 mg dose ≥2 hours pre-exercise—do not exceed one dose per 24 hours if already on maintenance therapy :contentReference[oaicite:14]{index=14}.
• Older children/adolescents: Move to higher strengths (5 mg or 10 mg) based on age under medical guidance.
• Missed dose: Skip and continue normal schedule; don’t double dose :contentReference[oaicite:15]{index=15}.
• Modification: No dosage adjustment needed in renal impairment. Caution in severe hepatic disease; consult a clinician.

Administration advice: Evening dosing is preferred for asthma; consistency is important. For rhinitis, choose a convenient time with patient adherence in mind.

Possible side effects of ALLAIR 4mg

• Common (≥1 %): Headache, abdominal pain, cough, fever, runny nose, diarrhea, earache—usually mild and transient :contentReference[oaicite:16]{index=16}.
• Less common: Nausea, vomiting, fatigue, rash, paresthesia, muscle cramps, sinusitis :contentReference[oaicite:17]{index=17}.
• Serious (rare): Neuropsychiatric events (agitation, aggression, depression, suicidal ideation)—boxed warning present since 2020 :contentReference[oaicite:18]{index=18}.
• Allergic reactions: Angioedema, hypersensitivity, urticaria, Stevens-Johnson syndrome—discontinue and seek care :contentReference[oaicite:19]{index=19}.
• Churg–Strauss syndrome: Eosinophilic vasculitis reported—usually in asthma patients tapering steroids :contentReference[oaicite:20]{index=20}.
• Hepatic issues: Rare elevations in liver enzymes; monitor in patients with liver disease or alcohol use :contentReference[oaicite:21]{index=21}.

Management: Monitor for any mood/behavior changes, especially early in treatment. Report serious symptoms immediately and discontinue drug if necessary.

ALLAIR 4mg Contraindications ALLAIR 4mg

• Hypersensitivity: Any known allergy to montelukast or excipients (e.g., aspartame in chewables) :contentReference[oaicite:22]{index=22}.
• Phenylketonuria (PKU): Chewable tablets contain phenylalanine from aspartame—use granules instead for PKU patients :contentReference[oaicite:23]{index=23}.
• Acute asthma exacerbations: Not a rescue medication—never use during an asthma attack :contentReference[oaicite:24]{index=24}.
• Neuropsychiatric risks: Use caution in patients with behavioral history—risk vs benefit must be assessed :contentReference[oaicite:25]{index=25}.

Note: Use in PKU or during acute attacks warrants alternative strategies. Pre-existing psychiatric illness may require close monitoring or alternative treatments.

Storage of ALLAIR 4mg

• Temperature: Store between 15–30 °C (59–86 °F) in original blister packaging :contentReference[oaicite:26]{index=26}.
• Humidity & light: Protect from moisture, heat, direct sunlight. Keep blister sealed.
• Child safety: Store out of reach—even though tablets are chewable.
• Expiry & disposal: Discard after expiration using take‑back programs—not down the toilet :contentReference[oaicite:27]{index=27}.

Reminder: Retain packaging for labeling and expiry information. Moisture or heat exposure may degrade the active compound—avoid bathroom storage.